{
    "pmcid": "9043892",
    "qa_pairs": {
        "What is a key advantage of nanobodies over conventional antibodies according to the paper?": [
            "Their ability to access cryptic epitopes",
            "Their ability to bind to the nucleocapsid protein",
            "Their ability to induce a stronger immune response",
            "Their ability to be administered orally"
        ],
        "What is the primary target for neutralizing antibodies against SARS-CoV-2 as discussed in the paper?": [
            "The receptor-binding domain (RBD) of the spike protein",
            "The nucleocapsid protein",
            "The membrane protein",
            "The envelope protein"
        ],
        "What potential delivery method for nanobody therapies is highlighted for targeting the respiratory tract?": [
            "Inhalation therapies",
            "Intravenous injection",
            "Oral administration",
            "Transdermal patches"
        ],
        "Which epitope groups are identified as targets for high-potency nanobodies?": [
            "RBD-2 and RBD-6",
            "RBD-1 and RBD-4",
            "RBD-5A and RBD-5B",
            "RBD-3 and RBD-7"
        ],
        "Which mutations in the spike protein are mentioned as affecting antibody binding efficacy?": [
            "E484K and N501Y",
            "D614G and P681R",
            "L452R and T478K",
            "K417N and L18F"
        ]
    }
}